Abstracts Archive - Page 134 of 2425 - ACR Meeting Abstracts

Abstract Number: 1928 • ACR Convergence 2024
Utilization of Rapid Telehealth Visits by Advanced Practice Providers for New Patients Referred to a Large Academic Practice with Low Suspicion for Rheumatologic Disease
Naomi Amudala¹, Sheilagh McCauley², Andrew Kanoff³, Joelle Koplin², Peter Merkel⁴ and Ethan Craig⁵, ¹University of Pennsylvania, Philadelphia, ²Penn Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Wallingford, PA
Background/Purpose: In most areas in the United States, access to rheumatologists for an initial evaluation is a major challenge resulting in long wait times for…
Abstract Number: 1973 • ACR Convergence 2024
Radioisotopic Synoviorthesis: Factors Associated with Good Response Evaluated by Ultrasound
Camille Bourgeois¹, Patricio Cardoso-Peñafiel², Beatriz Villapún Burgoa³, Rebeca Perez Pascual³, Juan Carlos Nieto Gonzalez¹, José María Álvaro-Gracia⁴, Enrique Calvo-Aranda² and Juan Molina-Collada³, ¹Hospital Universitario Gregorio Marañón, Madrid, Spain, ²Hospital Universitario Infanta Leonor, Madrid, Spain, ³Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Hospital Gregorio Marañón, Madrid, Spain
Background/Purpose: Radioisotopic synoviorthesis (RS) is an intra-articular local therapy that uses radioisotopes for the treatment of chronic recurrent synovitis with inadequate response to conventional therapy.…
Abstract Number: 1968 • ACR Convergence 2024
Development and Validation of an Arthritis-Detection Algorithm Using Thermal Imaging in Adults and Children
Thomason Jenna¹, Sullivan Erin², Rajdeep Pooni³, Liau Adriel⁴, Sadie Van den Bogaerde⁵, Audrey Luey⁶, Iris Hamilton⁷, Sriya Paluvayi⁶, Megan Tran¹, Janeth Robles-Navarro¹, Ian Muse⁸, Ava Klein⁴, Tzielan Lee⁹, Grant Hughes⁵, Alison Bays⁵, Elizabeth Ferucci¹⁰, Debosmita Biswas¹¹, Savannah Patridge¹¹ and Yongdong (Dan) Zhao¹², ¹University of Washington, Division of Rheumatology, Seattle, WA, ²Biostatistics, Epidemiology, and Analytics in Research (BEAR) Core, Seattle Children’s Research Institute, Seattle, WA, ³Stanford University, Palo Alto, CA, ⁴Seattle Children’s Research Institute, University of Washington, Seattle, ⁵University of Washington, Seattle, WA, ⁶Seattle Children’s Research Institute, University of Washington, Seattle, WA, ⁷Seattle Children's Hospital, Seattle, ⁸Seattle Children's Research institute, Seattle, WA, ⁹Stanford University School of Medicine, Palo Alto, CA, ¹⁰Alaska Native Tribal Health Consortium, Anchorage, AK, ¹¹University of Washington, Department of Radiology, Seattle, WA, ¹²University of Washington, Redmond, WA
Background/Purpose: The Thermal imaging-based Temperature After Within-limb Calibration (TAWiC) algorithm for the detection of arthritis in the knees has been validated in children by our…
Abstract Number: 1978 • ACR Convergence 2024
Insertional and Midportion Achilles Tendinopathy Have Differences in Presence of Calcifications and Neovascularization
Andy Smith¹, Hayley Powell Smitheman¹ and Karin Silbernagel², ¹University of Delaware, Newark, DE, ²University of Delaware, Avondale, PA
Background/Purpose: Achilles tendinopathy is the clinical diagnosis of a painful injury to the Achilles tendon associated with pain during tendon loading and structural changes within…
Abstract Number: 1774 • ACR Convergence 2024
Metabolomics and Lipidomics in Juvenile Localized Scleroderma
Yuan Zhang¹, Angela Aquilani², Rebecca Nicolai³, Fabrizio De Benedetti⁴, Emiliano Marasco² and Cristina Maglio¹, ¹University of Gothenburg, Gothenburg, Sweden, ²Bambino Gesù Children’s Hospital, Immunology and Rheumatology Unit, Roma, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Juvenile localised scleroderma (jLS) is a rare rheumatic disease in children characterized by inflammation and fibrosis in the skin [1, 2]. The cause and…
Abstract Number: 1989 • ACR Convergence 2024
Higher Early Cumulative Glucocorticoid Exposure Is Associated with Worse Progression-Free Survival in Patients with Immune Checkpoint Inhibitor Inflammatory Arthritis
Minerva Nong¹, Deanna Jannat-Khah², Karmela Kim Chan², Nilasha Ghosh³ and Anne Bass⁴, ¹Hospital for Special Surgery, Tampa, FL, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Although immune checkpoint inhibitors (ICI) have transformed cancer treatment, they unleash a range of immune-related adverse events (irAE), including inflammatory arthritis (ICI-IA). Glucocorticoids are…
Abstract Number: 1952 • ACR Convergence 2024
Interest in Clinical Trial Participation Among People with Lupus: Results from the Research Accelerated by You (RAY) Registry
Michael Fisher¹, Mimi Kim², Joan Merrill³, Safoah Agyemang¹ and Joy Buie¹, ¹Lupus Foundation of America, Washington, DC, ²Albert Einstein College of Medicine, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: With many treatments under study for SLE, a crisis in recruiting sufficient numbers of qualified patients for clinical trials has emerged. Willingness to consider…
Abstract Number: 1991 • ACR Convergence 2024
Initial Corticosteroid Dosing and Effects on Disease Activity, Survival, and Tumor Progression in Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Muhammad Bukhari¹, Ami Shah², Clifton Bingham³, Michelle Jones⁴ and Laura Cappelli¹, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Medicine, Pittsburgh, PA
Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) occurs in 3-7% of patients receiving ICI therapy for cancer. ICI-IA is routinely treated with corticosteroids, however, there…
Abstract Number: 1536 • ACR Convergence 2024
Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
JM JANSZ¹, EA Troy², WL Galanter³, Elaine Adams⁴, Nadera Sweiss⁵ and HJ CHANG⁶, ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois at Chicago, Woodridge, IL, ³University of Illinois at Chicago; Jesse Brown VA Medical Center, CHICAGO, IL, ⁴Jesse Brown VA Medical Center, La Grange, IL, ⁵University of IL, Chicago, IL, ⁶RHEUMATOLOGIST, CHICAGO, IL
Background/Purpose: Lupus nephritis is a well-known and severe complication in patients with systemic lupus erythematosus (SLE) that can lead to significant morbidity and mortality. Angiotensin-converting…
Abstract Number: 1791 • ACR Convergence 2024
A Transcriptomic Lupus Activity Signature Associates with Cardiovascular Function
Matthew Muller¹, Elliot Luttrell-Williams¹, Haley Rosmann², Kelly Ruggles³, Jill Buyon⁴ and Jeffrey Berger¹, ¹NYU Langone, New York City, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU Grossman School of Medicine, Brooklyn, NY, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder associated with increased cardiovascular risk. Platelet activity is increased in SLE and may mediate, in…
Abstract Number: 1806 • ACR Convergence 2024
Bisphenol a Methylation Scores Associate with SLE and ClinicalSubphenotypes
Holme Vestin¹, Nina Oparina², Maija-Leena Eloranta¹, Martina Frodlund³, Iva Gunnarsson⁴, Christopher Sjowall⁵, Elisabet Svenungsson⁶, Lars Rönnblom¹, Ann-Christine Syvänen¹, Johanna Sandling¹, Juliana Imgenberg-Kreuz¹ and Dag Leonard¹, ¹Uppsala university, Uppsala, Sweden, ²UU, Uppsala, Sweden, ³Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁴Karolinska Institute, Stockholm, Sweden, ⁵Linköping University, Linköping, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by production of auto-antibodies, immune complex formation and an activated type I interferon system. Both genetic and environmental…
Abstract Number: 1969 • ACR Convergence 2024
Harmonising Consensus and Reliability Studies in Musculoskeletal Ultrasound
Peter Mandl¹, Stine Carstensen², Lene Terslev³, Carlos Pineda⁴, Helen Keen⁵ and Maria-Antonietta D'Agostino⁶, and OMERACT Ultrasound Working Group, ¹Department of Rheumatology, Medical University of Vienna, vienna, Austria, ²Copenhagen Center for Arthritis Research and Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ⁴Instituto Nacional de Rehabilitacion, Mexico City, Mexico, ⁵University of Western Australia, Daglish, Western Australia, Australia, ⁶Department of Rheumatology, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, Rome, Italy
Background/Purpose: Over the last 20 years musculoskeletal ultrasound (MSUS) was established as a disease outcome measurement instrument. MSUS target domains, including consensual theoretical definitions of pathological…
Abstract Number: 1005 • ACR Convergence 2024
Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib
Nur Barlas, Sait Barlas, Stefan Milutinovic and Shristi Basnyat, Florida State University College of Medicine Internal Medicine Residency Program at Lee Health, Cape Coral
Background/Purpose: Janus Kinase (JAK) inhibitors are the agents of choice for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis when other DMARDs are…
Abstract Number: 1552 • ACR Convergence 2024
Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial
Ronald Van Vollenhoven¹, Joseph Merola², Kathryn H. Dao³, Piotr Leszczynski⁴, Marilyn Pike⁵, Samantha Pomponi⁶, Coburn Hobar⁶, Matthew J. Colombo⁶, Ravi Koti⁶, Subhashis Banerjee⁶, Thomas Wegman⁷ and Eric Morand⁸, ¹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ²UT Southwestern Medical Center, Newton, MA, ³Department of Internal Medicine, Division of Rheumatology, The University of Texas Southwestern Medical Center, Dallas, ⁴Department of Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland, ⁵Rheumatology, MedPharm Consulting, Inc., Raleigh, NC, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Beaver Falls, PA, ⁸School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of moderate to severe plaque…
Abstract Number: 1972 • ACR Convergence 2024
Quantifying Sjogren’s Disease Burden: UHFUS Evaluation of the Number and Severity of Involved Exocrine Gland
Giovanni Fulvio¹, Rossana Izzetti², Valentina Donati³, Caterina Porciani⁴, Silvia Fonzetti¹, Gaetano La Rocca¹, Inmaculada Conception Navarro García¹, Francesco Ferro⁵, Chiara Baldini¹ and Marta Mosca¹, ¹University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ²University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine - Unit of Dentistry and Oral Surgery, Pisa, ³Azienda Ospedaliero-Universitaria Pisana, Unit of Pathological Anatomy 2, Pisa, Italy, ⁴University of Pisa, Department of Clinical and Experimental Medicine - Immmunology and Allergology Unit, Pisa, Italy, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy
Background/Purpose: Ultra-high frequency ultrasound (UHFUS) has emerged as a promising tool for evaluating small superficial exocrine glands including lachrymal (LGs) and labial salivary glands (LSGs)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].